WCM Investment Management LLC increased its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 56.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 245,997 shares of the company's stock after buying an additional 88,520 shares during the quarter. WCM Investment Management LLC owned about 0.13% of Revolution Medicines worth $9,188,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of RVMD. Russell Investments Group Ltd. boosted its holdings in shares of Revolution Medicines by 11.4% in the 4th quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company's stock valued at $186,000 after acquiring an additional 434 shares during the last quarter. Amalgamated Bank grew its position in Revolution Medicines by 8.3% during the 4th quarter. Amalgamated Bank now owns 5,707 shares of the company's stock worth $250,000 after purchasing an additional 435 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in shares of Revolution Medicines by 5.0% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 11,398 shares of the company's stock valued at $498,000 after buying an additional 545 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Revolution Medicines by 11.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,221 shares of the company's stock valued at $232,000 after buying an additional 615 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Revolution Medicines by 2.0% in the 4th quarter. Arizona State Retirement System now owns 33,905 shares of the company's stock valued at $1,483,000 after buying an additional 650 shares during the period. 94.34% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
RVMD has been the topic of several analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $57.00 target price on shares of Revolution Medicines in a report on Tuesday, June 24th. Stifel Nicolaus lowered their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Wedbush reaffirmed an "outperform" rating and set a $73.00 price objective (up previously from $67.00) on shares of Revolution Medicines in a research note on Tuesday, June 24th. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price (down from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Finally, Oppenheimer increased their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $67.58.
Check Out Our Latest Analysis on Revolution Medicines
Revolution Medicines Trading Down 0.5%
NASDAQ:RVMD traded down $0.19 during trading hours on Thursday, reaching $37.00. 1,106,610 shares of the company were exchanged, compared to its average volume of 1,668,972. The firm has a market cap of $6.89 billion, a PE ratio of -9.25 and a beta of 1.06. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The stock's 50-day moving average is $39.61 and its 200-day moving average is $39.82.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same period last year, the firm earned ($0.70) EPS. As a group, research analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current year.
Revolution Medicines Profile
(
Free Report)
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
See Also
Before you consider Revolution Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revolution Medicines wasn't on the list.
While Revolution Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
